Abstract
BackgroundResistance to immune checkpoint inhibitors (ICIs) is common even in tumors with T cell inflammation.1 2 To this end, we interrogated sequelae of ICI-induced T cell inflammation. The current paradigm...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
